<DOC>
	<DOCNO>NCT00993343</DOCNO>
	<brief_summary>To evaluate rapamune + tacrolimus immunosuppressive prophylaxis well establish therapy use cyclosporine methotrexate , Nordic prospective multicenter randomize study perform . Patients randomize treatment rapamune combine tacrolimus , establish therapy use cyclosporine methotrexate .</brief_summary>
	<brief_title>Randomized Trial Comparing Sirolimus Tacrolimus Versus Cyclosporine Methotrexate Graft-versus-host Disease ( GVHD ) Prophylaxis After Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>Primary endpoint The primary endpoint grade II-IV acute GVHD two group . GVHD diagnose clinically grade 0 IV . The diagnosis clinical biopsy skin , liver gut use accord routine participate center . Other study parameter 1 . Time neutrophils &gt; 0.5 x 109/L . 2 . Time platelets &gt; 20 x 109/L 50 x 109/L . 3 . Platelet level 30 day transplant . 4 . Transfusion requirement platelet , erythrocyte , granulocyte transfusion first 30 day . 5 . Non-engraftment ( graft failure/rejection ) . 6 . Grade acute GVHD . 7 . Incidence chronic graft-versus-host disease grade limited extensive mild , moderate severe . 8 . Transplant-related mortality . 9 . Probability relapse patient haematological malignancy . 10 . Survival . 11 . Relapse-free survival . 12 . Infections bacteria , virus fungi . Cytomegalovirus reactivation also follow PCR . 13 . Side-effects . Side-effects regard hematopoiesis , liver test , renal function , cardiac function , neurology , endocrinology , etc. , take patient ' chart . These parameter follow regularly transplantation . Inclusion criterion Chronic myeloid leukemia ( CML ) 1st 2nd chronic phase , acute myeloid leukemia ( AML ) complete remission , acute lymphoblastic leukemia ( ALL ) complete remission , myelodysplastic syndrome , chronic lymphocytic leukemia , lymphoma , non-malignant disorder , severe aplastic anemia , hemoglobinopathies metabolic disorder</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Chronic myeloid leukemia ( CML ) 1st 2nd chronic phase , acute myeloid leukemia ( AML ) complete remission , acute lymphoblastic leukemia ( ALL ) complete remission , myelodysplastic syndrome , chronic lymphocytic leukemia , lymphoma , nonmalignant disorder , severe aplastic anemia , hemoglobinopathies metabolic disorder Recipients major HLAmismatched graft . Patients addict drug alcohol . Patients receive stem cell source bone marrow peripheral stem cell , instance cord blood transplant . Patients relapse blast crisis malignant disease . Prior allogeneic transplant use hematopoietic stem cell source Seropositive human immunodeficiency virus ( HIV ) Uncontrolled bacterial , viral , fungal infection ( progression clinical symptom ) Pregnant ( positive serum human chorionic gonadotropin [ βHCG ] test ) breastfeeding within 4 week study entry Kidney function : serum creatinine outside normal range age , measure creatinine clearance le 40 mL/min/1.72m² within 4 week study entry proteinuria &gt; 0.3 g/day Liver function : recent direct bilirubin , ALT , AST great two time upper limit normal within 4 week study entry Lung disease : adult , FVC FEV1 le 60 % predict value ( correct hemoglobin ) ; child , overt hypoxemia , measure oxygen saturation le 92 % within 4 week study entry Cardiac ejection fraction le 45 % adult child , le 26 % shorten fraction child within 4 week study entry Cholesterol level great 300 mg/dL triglyceride level great 300 mg/dL treat , appropriate lipidlowering therapy within 4 week study entry Karnofsky score &lt; 70 % Prior history allergy sirolimus Requires voriconazole time study entry Currently receive another investigational drug unless clear principal investigator sponsor Patients receive BuCy conditioning therapy</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>GVHD</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>sirolimus</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>allogeneic</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>Relapse-free survival</keyword>
</DOC>